Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

NCT02100436 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

270

Enrollment

NIH

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)